Have a feature idea you'd love to see implemented?
Let us know!
DXCM Dexcom Inc
Price (delayed)
$80.04
Market cap
$31.26B
P/E Ratio
46
Dividend/share
N/A
EPS
$1.74
Enterprise value
$33.18B
DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. It operates internationally with headquarters in San Diego, California. Dexcom was founded in
Highlights
Dexcom's net income has soared by 81% YoY and by 2.1% from the previous quarter
The EPS has soared by 78% YoY
The company's equity fell by 19% QoQ and by 13% YoY
The quick ratio has declined by 16% year-on-year and by 15% since the previous quarter
Key stats
What are the main financial stats of DXCM
Market
Valuations
Earnings
Shares outstanding
390.6M
Market cap
$31.26B
Enterprise value
$33.18B
Price to book (P/B)
16.21
Price to sales (P/S)
7.98
EV/EBIT
44.3
EV/EBITDA
34.51
EV/Sales
8.39
Revenue
$3.95B
Gross profit
$2.44B
Net income
$680.8M
EBIT
$748.8M
EBITDA
$961.2M
Free cash flow
$535M
Per share
Balance sheet
Liquidity
EPS
$1.74
EPS diluted
$1.66
Free cash flow per share
$1.36
Book value per share
$4.94
Revenue per share
$10.03
TBVPS
$15.79
Total assets
$6.35B
Total liabilities
$4.37B
Debt
$2.53B
Equity
$1.98B
Working capital
$2.53B
Debt to equity
1.28
Current ratio
2.46
Quick ratio
2.01
Net debt/EBITDA
1.99
Margins
Efficiency
Dividend
EBITDA margin
24.3%
Gross margin
61.7%
Net margin
17.2%
Operating margin
15.9%
Return on assets
10.5%
Return on equity
31.2%
Return on invested capital
11.6%
Return on capital employed
16.2%
Return on sales
18.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
DXCM stock price
How has the Dexcom stock price performed over time
Intraday
5.57%
1 week
3.69%
1 month
6.38%
1 year
-31.38%
YTD
-35.5%
QTD
19.39%
Financial performance
How have Dexcom's revenue and profit performed over time
Revenue
$3.95B
Gross profit
$2.44B
Operating income
$628M
Net income
$680.8M
Gross margin
61.7%
Net margin
17.2%
Dexcom's net income has soared by 81% YoY and by 2.1% from the previous quarter
The net margin has soared by 55% YoY
DXCM's operating income is up by 24% year-on-year but it is down by 8% since the previous quarter
Dexcom's revenue has increased by 16% YoY
Growth
What is Dexcom's growth rate over time
Valuation
What is Dexcom stock price valuation
P/E
46
P/B
16.21
P/S
7.98
EV/EBIT
44.3
EV/EBITDA
34.51
EV/Sales
8.39
The EPS has soared by 78% YoY
The stock's price to earnings (P/E) is 62% less than its 5-year quarterly average of 122.5 and 34% less than its last 4 quarters average of 69.4
DXCM's P/B is 24% below its 5-year quarterly average of 21.2 and 18% below its last 4 quarters average of 19.8
The company's equity fell by 19% QoQ and by 13% YoY
The stock's price to sales (P/S) is 49% less than its 5-year quarterly average of 15.7 and 30% less than its last 4 quarters average of 11.4
Dexcom's revenue has increased by 16% YoY
Efficiency
How efficient is Dexcom business performance
The ROE has soared by 80% year-on-year and by 5% since the previous quarter
Dexcom's ROA has soared by 69% YoY and by 2.9% from the previous quarter
DXCM's return on invested capital is up by 12% year-on-year but it is down by 6% since the previous quarter
The ROS fell by 8% QoQ but it rose by 7% YoY
Dividends
What is DXCM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for DXCM.
Financial health
How did Dexcom financials performed over time
The company's total assets is 45% higher than its total liabilities
The quick ratio has declined by 16% year-on-year and by 15% since the previous quarter
Dexcom's current ratio has decreased by 13% QoQ and by 12% YoY
The debt is 28% more than the equity
DXCM's debt to equity is up by 23% QoQ and by 9% YoY
The company's equity fell by 19% QoQ and by 13% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.